- ISIN
- US19249H1032
- CUSIP
- 19249H103
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Nov 6, 2014
Highlights
- Market Cap
- $207.33M
- Enterprise Value
- $93.04M
- EPS (TTM)
- $1.52
- PE Ratio
- 1.00
- Total Revenue (TTM)
- $46.88M
- Gross Profit (TTM)
- $23.41M
- EBITDA (TTM)
- -$162.15M
- Year Range
- $0.71 - $2.62
- Target Price
- $6.02
- ROA (TTM)
- 70.02%
- ROE (TTM)
- 236.91%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CHRS Performance Chart
Coherus BioSciences, Inc. (CHRS) is up 7.0% since the beginning of the year. At $2 per share, CHRS is trading 41.9% below its 52-week high of $3. Investors who bought $1,000 worth of CHRS shares 5 years ago would now be looking at an investment worth $117.
Loading charts...
Returns By Period
Coherus BioSciences, Inc. (CHRS) has returned 7.04% so far this year and 98.43% over the past 12 months. Over the last ten years, CHRS has returned -22.02% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.
Coherus BioSciences, Inc.
- 1D
- -3.18%
- 1M
- -15.56%
- YTD
- 7.04%
- 6M
- 31.03%
- 1Y
- 98.43%
- 3Y*
- -30.10%
- 5Y*
- -34.94%
- 10Y*
- -22.02%
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.25%
- YTD
- 11.16%
- 6M
- 11.43%
- 1Y
- 28.20%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
CHRS Monthly Returns History
Based on dividend-adjusted daily data since Nov 6, 2014, CHRS's average daily return is +0.04%, while the average monthly return is +0.53%. At this rate, an investment would double in approximately 10.9 years.
Historically, 49% of months were positive and 51% were negative. The best month was Nov 2024 with a return of +63.8%, while the worst month was May 2023 at -43.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.
On a daily basis, CHRS closed higher 47% of trading days. The best single day was Nov 20, 2024 with a return of +33.9%, while the worst single day was Nov 7, 2023 at -30.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 52.11% | -22.69% | 1.20% | 5.03% | -10.42% | -4.40% | 7.04% | ||||||
| 2025 | -14.49% | -5.93% | -27.30% | 27.63% | -24.37% | -6.12% | 28.57% | 23.38% | 41.38% | 2.44% | -19.05% | 4.41% | 2.90% |
| 2024 | -35.44% | 6.05% | 4.82% | -17.99% | -7.14% | -4.95% | -10.98% | -9.74% | -25.18% | -28.37% | 63.76% | 13.11% | -58.56% |
| 2023 | 7.07% | -20.17% | 1.03% | 5.70% | -43.43% | 4.40% | 12.88% | 10.58% | -29.83% | -10.43% | -36.42% | 56.34% | -57.95% |
| 2022 | -22.56% | -4.61% | 9.50% | -29.98% | -18.81% | -1.36% | 16.99% | 32.00% | -14.04% | -9.47% | -21.15% | 15.45% | -50.38% |
| 2021 | 8.17% | -13.62% | -10.04% | 1.30% | -11.08% | 5.09% | -5.64% | 22.45% | 0.56% | 4.11% | 11.00% | -14.05% | -8.17% |
Benchmark Metrics
Coherus BioSciences, Inc. has an annualized alpha of -8.23%, beta of 1.39, and R2 of 0.11 versus S&P 500 Index. Calculated based on daily prices since November 07, 2014.
- This stock participated in 132.00% of S&P 500 Index downside but only 11.18% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.11 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -8.23%
- Beta
- 1.39
- R²
- 0.11
- Upside Capture
- 11.18%
- Downside Capture
- 132.00%
Return for Risk
Risk / Return Rank
CHRS ranks 74 for risk / return — better than 74% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Coherus BioSciences, Inc. (CHRS) and compare them to S&P 500 Index.
| CHRS | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.22 | 2.39 | -1.17 |
Sortino ratioReturn per unit of downside risk | 1.95 | 3.25 | -1.30 |
Omega ratioGain probability vs. loss probability | 1.23 | 1.43 | -0.20 |
Calmar ratioReturn relative to maximum drawdown | 2.41 | 3.11 | -0.70 |
Martin ratioReturn relative to average drawdown | 4.45 | 14.38 | -9.93 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Coherus BioSciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Coherus BioSciences, Inc. was 98.21%, occurring on Nov 4, 2024. The portfolio has not yet recovered.
The current Coherus BioSciences, Inc. drawdown is 95.94%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2024 bear market2024 | -98.21%Nov 2024 | 9y 3mo | — | 10y 10moJul 2015 - now |
2015 bear market2015 | -35.86%May 2015 | 2mo 6d | 2mo 3d | 4mo 9dMar 2015 - Jul 2015 |
2015 correction2015 | -17.86%Feb 2015 | 7d | 9d | 16dFeb 2015 - Feb 2015 |
2014 correction2014 | -16.38%Dec 2014 | 1mo 8d | 7d | 1mo 15dNov 2014 - Dec 2014 |
2015 correction2015 | -11.46%Jan 2015 | 8d | 6d | 14dJan 2015 - Jan 2015 |
Drawdown Indicators
| CHRS | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.21% | -56.78% | -41.43% |
Max Drawdown (1Y)Largest decline over 1 year | -41.04% | -9.10% | -31.94% |
Max Drawdown (3Y)Largest decline over 3 years | -87.71% | -18.90% | -68.81% |
Max Drawdown (5Y)Largest decline over 5 years | -96.47% | -25.43% | -71.04% |
Max Drawdown (10Y)Largest decline over 10 years | -97.88% | -33.92% | -63.96% |
Current DrawdownCurrent decline from peak | -95.94% | 0.00% | -95.94% |
Average DrawdownAverage peak-to-trough decline | -63.47% | -10.72% | -52.75% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 22.21% | 1.97% | +20.24% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Coherus BioSciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Coherus BioSciences, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for CHRS, comparing it with other companies in the Biotechnology industry. Currently, CHRS has a P/E ratio of 1.0. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CHRS relative to other companies in the Biotechnology industry. Currently, CHRS has a P/S ratio of 4.0. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CHRS in comparison with other companies in the Biotechnology industry. Currently, CHRS has a P/B value of 2.6. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CHRS
Add Coherus BioSciences, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CHRS